Quick answer: Testosterone is not just a male hormone — women produce testosterone in the ovaries and adrenal glands, and it plays essential roles in libido, energy, muscle maintenance, bone density, mood, and cognitive sharpness. Female testosterone levels decline 50% between ages 20 and 45, typically long before estrogen declines. Low testosterone in women is associated with low libido (the most clinically recognized symptom), fatigue, difficulty building muscle despite exercise, reduced motivation and drive, and mood flatness — symptoms that are frequently misattributed to depression, thyroid dysfunction, or “just aging.” The optimal female total testosterone range for symptoms resolution is typically 25–60 ng/dL — with free testosterone above 1.5 pg/mL being more clinically relevant than total testosterone alone.
Testosterone in Women: Physiology and Normal Production
In women, testosterone is produced by three sources: the ovaries (approximately 25%), the adrenal glands (approximately 25%), and peripheral conversion from precursor hormones (primarily DHEA and androstenedione, approximately 50%). Unlike estrogen, which drops precipitously at menopause, testosterone declines gradually across the reproductive years — most women have approximately half the testosterone at 45 that they had at 20. Women who undergo surgical menopause (bilateral oophorectomy) experience an immediate and profound drop in both estrogen and testosterone, producing the most severe and acute hypoactive sexual desire disorder (HSDD) — directly linking ovarian testosterone to female sexual function.
Normal female testosterone ranges in standard labs are typically 15–70 ng/dL total testosterone, but these ranges are wide, poorly age-stratified, and derived from population distributions rather than symptomatic outcomes. The functional medicine optimal range for symptomatic women is 25–60 ng/dL total testosterone, with free testosterone (unbound, biologically active fraction) above 1.0–2.0 pg/mL. As with men, SHBG (sex hormone-binding globulin) strongly influences free testosterone availability. Women on oral contraceptives or oral estrogen have dramatically elevated SHBG (OCPs can increase SHBG 2–4 fold), binding most available testosterone and producing androgen deficiency symptoms — often misidentified as “depression” or “OCP side effects.”
Symptoms of Low Testosterone in Women
Sexual health: The most studied and most consistently testosterone-responsive symptom in women. Hypoactive sexual desire disorder (HSDD) — defined as low libido causing personal distress — is the most prevalent female sexual dysfunction, affecting approximately 10–15% of premenopausal and 30–50% of postmenopausal women. Multiple RCTs and a 2019 Lancet meta-analysis confirm transdermal testosterone significantly improves desire, arousal, frequency of satisfying sexual activity, and orgasm quality in postmenopausal women with HSDD — with the largest evidence base of any intervention for this condition. The mechanism: testosterone acts on androgen receptors in the brain’s hypothalamic-limbic system, genital tissues (clitoral and vaginal), and sensory neurons to support sexual interest and response.
Energy and vitality: Testosterone is a direct metabolic hormone — it stimulates mitochondrial biogenesis and red blood cell production (via EPO stimulation) in women as in men. Low testosterone in women produces fatigue that differs from thyroid- or adrenal-driven fatigue: it is specifically a loss of physical vitality and stamina rather than overwhelming exhaustion, often described as “I can function but feel dulled” rather than “I cannot get off the couch.” Women with low testosterone often find that they no longer get the endorphin benefit from exercise — because testosterone amplifies the exercise response.
Body composition: Testosterone is an anabolic hormone that promotes muscle protein synthesis and inhibits fat storage. Women with low testosterone gain fat more easily (particularly visceral fat), lose muscle mass despite resistance training, and find it difficult to change body composition even with significant effort. The post-40 body composition shift — muscle loss with fat gain without equivalent changes in diet or exercise — is often significantly testosterone-driven, not just estrogen-driven or aging-related.
Mood and cognition: Testosterone receptors exist throughout the female brain, including the prefrontal cortex (dopaminergic regulation), limbic system (mood), and hippocampus (memory). Low testosterone in women produces mood flatness (similar to dopamine deficiency — a lack of enthusiasm and drive rather than sadness), reduced confidence and assertiveness, cognitive slowing, and verbal memory decline. These symptoms are often diagnosed as depression or anxiety and treated with SSRIs — which may be appropriate if the underlying cause is serotonergic — but miss the androgenic component entirely if testosterone is not measured.
Bone density: Testosterone contributes to bone density in women via androgen receptors on osteoblasts — independent of estrogen’s mechanism. Low testosterone (alongside low estrogen) accelerates bone density loss. Women with premature ovarian insufficiency or surgical menopause, who lose both estrogen and testosterone simultaneously, have particularly elevated osteoporosis risk that cannot be fully addressed by estrogen-only replacement.
Causes of Low Testosterone in Women
Age and ovarian decline: The gradual decline in ovarian testosterone production from the 20s onward means that testosterone deficiency often precedes estrogen deficiency by decades. Many women in their 30s have testosterone levels equivalent to a 70-year-old man — producing symptoms that are normalized as “just how I feel now” because no one measures or treats it. Surgical menopause (oophorectomy) produces immediate severe testosterone drop.
Oral contraceptives: Oral contraceptives suppress LH (via hypothalamic-pituitary feedback inhibition from synthetic progestins and estrogens), reducing ovarian testosterone production by approximately 50–60%. Simultaneously, the oral estrogen component dramatically increases SHBG — binding and deactivating the remaining testosterone. The result is free testosterone depletion that can persist months to years after discontinuing OCPs (because SHBG remains elevated even after LH recovers). Women who notice low libido, mood changes, and fatigue after starting OCPs — or who cannot identify a cause for these symptoms in the years following OCP discontinuation — may have OCP-induced androgen deficiency.
HPA axis dysfunction and chronic stress: Chronic cortisol elevation suppresses LH pulsatility (reducing ovarian testosterone production) and reduces DHEA (the adrenal precursor to testosterone in peripheral tissues). Highly stressed women often have the dual-deficiency of low testosterone and low DHEA alongside elevated cortisol — a pattern that produces the combined symptoms of low energy, low libido, and mood dysfunction.
Low cholesterol and very low-fat diets: Testosterone (and all steroid hormones) is synthesized from cholesterol. Very low-fat diets and statin-driven low LDL cholesterol can reduce sex hormone synthesis. This is one mechanism behind reduced libido and sexual dysfunction in people on statin therapy — and a consideration for women on very low-fat plant-based diets with cholesterol below 150 mg/dL.
PCOS: Counterintuitively, many women with PCOS have elevated total testosterone but are not androgen-deficient symptomatically — their testosterone is elevated due to insulin resistance-driven LH excess. After PCOS is treated (insulin sensitization, ovarian normalization), some women’s testosterone may normalize to a lower range, potentially revealing underlying relative androgen deficiency. PCOS management should monitor both ends of the androgen spectrum.
Testing Testosterone in Women
Female testosterone testing requires the same comprehensive panel as male testosterone assessment: total testosterone, free testosterone, SHBG, DHEA-S, and sex hormone panel (estradiol, progesterone). Standard lab total testosterone testing often has inadequate sensitivity at female levels — mass spectrometry (LC-MS/MS) methods are significantly more accurate than immunoassay methods for female testosterone measurement and are available through specialty labs (Labcorp endocrine services, Quest androgen panel). The timing of testing matters: testosterone fluctuates throughout the menstrual cycle (peaking around ovulation) and should be tested in the morning (highest time of day) for consistent comparisons.
DHEA-S (dehydroepiandrosterone sulfate) is the adrenal precursor to testosterone and an important parallel marker. DHEA-S peaks in the mid-20s and declines approximately 10% per decade — most 50-year-old women have DHEA-S levels 50% below their peak. DHEA-S supplementation (25–50 mg/day) can raise both DHEA-S and free testosterone in women and is a commonly used androgen restoration approach — particularly in postmenopausal women with low adrenal androgen production.
Natural Approaches to Optimize Female Testosterone
Resistance Training: The Primary Non-Pharmacological Intervention
Resistance training is the single most effective natural testosterone-raising intervention in women. Compound movements (squats, deadlifts, hip hinges, pull-ups) with moderate to heavy loads produce acute testosterone elevation post-exercise and, with consistent practice, increase baseline free testosterone by reducing SHBG (resistance training consistently lowers SHBG in women) and increasing androgen receptor sensitivity in muscle tissue. Two to three resistance training sessions per week, progressing in load over time, produces measurable free testosterone increases within 8–12 weeks. The additional benefit: lean mass increase further reduces SHBG (muscle tissue is androgenic, reducing SHBG synthesis in the liver).
DHEA Supplementation
DHEA is a precursor that converts to testosterone (and estrogen) in peripheral tissues. DHEA supplementation (25–50 mg/day in postmenopausal women; 25 mg/day starting dose in perimenopausal women) raises free testosterone and reduces HSDD symptoms in multiple RCTs. The FDA-approved intravaginal DHEA product (Prasterone/Intrarosa) specifically treats genitourinary syndrome of menopause (vaginal atrophy and pain) via local androgen conversion. Systemic DHEA at 25–50 mg/day raises total testosterone by 20–40% in postmenopausal women. Testing DHEA-S before and after supplementation confirms response and prevents over-supplementation.
Zinc and Micronutrient Optimization
Zinc (30 mg zinc bisglycinate/day) reduces SHBG and supports androgen synthesis in women as in men. Vitamin D repletion (to 50–80 ng/mL) supports LH-stimulated ovarian testosterone production. Magnesium reduces SHBG binding affinity, increasing free testosterone. Adequate dietary fat (from olive oil, avocados, eggs, and fatty fish) provides cholesterol for sex hormone synthesis. These nutritional foundations apply equally to female and male sex hormone optimization.
HPA Axis Support
Cortisol reduction via ashwagandha (300–600 mg KSM-66/day), sleep optimization, and stress management indirectly raises testosterone by reducing the cortisol-mediated LH suppression and DHEA depletion that drive androgen deficiency in stressed women. This is particularly relevant for women in their 30s and 40s whose testosterone deficiency symptoms coincide with high-stress life phases (career peak, raising children, sandwich generation caregiving responsibilities).
Discontinuing Oral Contraceptives (When Appropriate)
For women whose androgen deficiency symptoms correlate with OCP use, transitioning to non-hormonal or progestin-only (lower SHBG impact) contraceptive methods may be appropriate if the symptoms are severe. SHBG normalization typically takes 6–12 months after OCP discontinuation. This is a significant decision that requires comprehensive reproductive health counseling — but the SHBG-testosterone-OCP connection is sufficiently established that it warrants consideration in women with clear OCP-temporal symptom onset.
Testosterone Therapy for Women: When and How
The Endocrine Society (2019 position statement) and the International Menopause Society (2019 Global Consensus Statement) both endorse transdermal testosterone therapy for postmenopausal women with HSDD — making it the most guideline-endorsed indication for female testosterone therapy. The recommended approach: low-dose transdermal testosterone (typically 1/10th the male dose — achieving female physiological levels, not male supraphysiological levels). A testosterone cream or gel compounded to achieve 25–50 ng/dL total testosterone is the most commonly used formulation. The FDA has not approved any testosterone product specifically for women in the US, but off-label use of male products at lower doses or compounded female-specific preparations are standard practice in menopause medicine.
Safety concerns for female testosterone therapy: androgenic side effects (acne, increased body hair, clitoral sensitivity changes) occur when testosterone exceeds physiological female ranges — avoided by targeting laboratory values in the female optimal range rather than male ranges. Cardiovascular safety is favorable at physiological replacement doses. Breast cancer concerns remain unresolved by long-term RCT data — observational data is mixed, and the FDA’s conservative stance reflects regulatory caution rather than established harm. Women with personal or strong family history of hormone-receptor-positive breast cancer should discuss individual risk with an oncologist before proceeding.
The Bottom Line
Female testosterone deficiency is common, underdiagnosed, and undertreated. The standard hormone panel for perimenopausal and postmenopausal women focuses almost exclusively on estrogen and progesterone — leaving the androgen picture unmeasured and unaddressed. Women experiencing low libido, fatigue, difficulty with body composition despite exercise effort, mood flatness, or cognitive sluggishness deserve a complete hormone evaluation including free testosterone, DHEA-S, and SHBG. For many women, targeted interventions — resistance training, DHEA supplementation, zinc/vitamin D/magnesium optimization, cortisol reduction — produce significant symptomatic improvement without pharmacological testosterone. When those interventions are insufficient, guideline-supported transdermal testosterone at physiological female doses is a legitimate, evidence-backed option.
If you are experiencing symptoms consistent with female androgen deficiency — low libido, fatigue, mood changes, difficulty maintaining muscle, or cognitive changes — a comprehensive female hormone panel is the appropriate first step. Call our office at (810) 206-1402 for a functional medicine evaluation including complete female hormone assessment and individualized optimization protocol.
Frequently Asked Questions
Do women need testosterone?
Yes — women produce and require testosterone for libido, energy, mood, muscle maintenance, bone density, and cognitive function. Female testosterone levels are 10–20 times lower than male levels but are no less physiologically essential. Testosterone declines 50% between ages 20 and 45 in most women — often before estrogen declines — and the resulting deficiency is significantly underdiagnosed because standard hormone panels often omit testosterone and clinical guidelines for female androgen deficiency lag behind male hypogonadism treatment protocols.
What are the signs of low testosterone in women?
The most common signs: low or absent sexual desire (HSDD — hypoactive sexual desire disorder), reduced arousal and orgasm difficulty, persistent fatigue and loss of vitality, difficulty gaining or maintaining muscle despite resistance training, easy fat gain especially visceral, mood flatness (lack of motivation, confidence, and drive distinct from depressed mood), cognitive slowing, and accelerated bone density loss. These symptoms frequently coexist and often begin in the 30s, well before menopausal estrogen decline.
Can oral contraceptives lower testosterone in women?
Yes — significantly. Oral contraceptives suppress LH (reducing ovarian testosterone production by 50-60%) and dramatically increase SHBG (binding and deactivating the remaining testosterone), producing free testosterone levels near zero. This is a primary mechanism of OCP-associated low libido, mood changes, and fatigue. The effect can persist 6-12 months after OCP discontinuation while SHBG normalizes. Women with clear temporal correlation between OCP use and androgen-deficiency symptoms should consider this mechanism in their evaluation.
Is testosterone therapy safe for women?
At physiological female doses (targeting 25-60 ng/dL total testosterone, not male levels), transdermal testosterone has a favorable safety profile in postmenopausal women per the 2019 Endocrine Society and International Menopause Society position statements. Androgenic side effects (acne, hair changes) occur at supraphysiological doses. Cardiovascular safety is favorable at replacement doses. Long-term breast cancer safety data from large RCTs is lacking — women with hormone-receptor-positive breast cancer history should discuss individual risk assessment with their oncologist before proceeding.